Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Hatching the behavioral addiction egg: Reward Deficiency Solution System (RDSS)™ as a function of dopaminergic neurogenetics and brain functional connectivity linking all addictions under a common rubric.

Blum K, Febo M, McLaughlin T, Cronjé FJ, Han D, Gold SM.

J Behav Addict. 2014 Sep;3(3):149-56. doi: 10.1556/JBA.3.2014.019. Epub 2014 Aug 26. Review.

2.

Coupling Neurogenetics (GARS™) and a Nutrigenomic Based Dopaminergic Agonist to Treat Reward Deficiency Syndrome (RDS): Targeting Polymorphic Reward Genes for Carbohydrate Addiction Algorithms.

Blum K, Simpatico T, Badgaiyan RD, Demetrovics Z, Fratantonio J, Agan G, Febo M, Gold MS.

J Reward Defic Syndr. 2015;1(2):75-80. Epub 2015 Jun 24.

3.

Genetic Addiction Risk Score (GARS): molecular neurogenetic evidence for predisposition to Reward Deficiency Syndrome (RDS).

Blum K, Oscar-Berman M, Demetrovics Z, Barh D, Gold MS.

Mol Neurobiol. 2014 Dec;50(3):765-96. doi: 10.1007/s12035-014-8726-5. Epub 2014 May 31.

4.

Hypothesizing That Neuropharmacological and Neuroimaging Studies of Glutaminergic-Dopaminergic Optimization Complex (KB220Z) Are Associated With "Dopamine Homeostasis" in Reward Deficiency Syndrome (RDS).

Blum K, Febo M, Fried L, Li M, Dushaj K, Braverman ER, McLaughlin T, Steinberg B, Badgaiyan RD.

Subst Use Misuse. 2017 Mar 21;52(4):535-547. doi: 10.1080/10826084.2016.1244551. Epub 2016 Dec 29.

5.

Neurogenetics of dopaminergic receptor supersensitivity in activation of brain reward circuitry and relapse: proposing "deprivation-amplification relapse therapy" (DART).

Blum K, Chen TJ, Downs BW, Bowirrat A, Waite RL, Braverman ER, Madigan M, Oscar-Berman M, DiNubile N, Stice E, Giordano J, Morse S, Gold M.

Postgrad Med. 2009 Nov;121(6):176-96. doi: 10.3810/pgm.2009.11.2087. Review.

6.

Neurogenetic Impairments of Brain Reward Circuitry Links to Reward Deficiency Syndrome (RDS): Potential Nutrigenomic Induced Dopaminergic Activation.

Blum K, Oscar-Berman M, Giordano J, Downs B, Simpatico T, Han D, Femino J.

J Genet Syndr Gene Ther. 2012 Oct 17;3(4). pii: 1000e115.

7.

Activation instead of blocking mesolimbic dopaminergic reward circuitry is a preferred modality in the long term treatment of reward deficiency syndrome (RDS): a commentary.

Blum K, Chen AL, Chen TJ, Braverman ER, Reinking J, Blum SH, Cassel K, Downs BW, Waite RL, Williams L, Prihoda TJ, Kerner MM, Palomo T, Comings DE, Tung H, Rhoades P, Oscar-Berman M.

Theor Biol Med Model. 2008 Nov 12;5:24. doi: 10.1186/1742-4682-5-24. Review.

8.

Molecular Genetic Testing in Reward Deficiency Syndrome (RDS): Facts and Fiction.

Blum K, Badgaiyan RD, Agan G, Fratantonio J, Simpatico T, Febo M, Haberstick BC, Smolen A, Gold MS.

J Reward Defic Syndr. 2015;1(1):65-68.

9.

Neurogenetics and gene therapy for reward deficiency syndrome: are we going to the Promised Land?

Blum K, Thanos PK, Badgaiyan RD, Febo M, Oscar-Berman M, Fratantonio J, Demotrovics Z, Gold MS.

Expert Opin Biol Ther. 2015 Jul;15(7):973-85. doi: 10.1517/14712598.2015.1045871. Epub 2015 May 14. Review.

PMID:
25974314
10.

Promoting Precision Addiction Management (PAM) to Combat the Global Opioid Crisis.

Blum K, Modestino EJ, Neary J, Gondré-Lewis MC, Siwicki D, Moran M, Hauser M, Braverman ER, Baron D, Steinberg B, Laughlin TM, Badgaiyan RD.

Biomed J Sci Tech Res. 2018 Jan 7;2(2):1-4. doi: 10.26717/BJSTR.2018.02.000738.

11.

Dopamine in the Brain: Hypothesizing Surfeit or Deficit Links to Reward and Addiction.

Blum K, Thanos PK, Oscar-Berman M, Febo M, Baron D, Badgaiyan RD, Gardner E, Demetrovics Z, Fahlke C, Haberstick BC, Dushaj K, Gold MS.

J Reward Defic Syndr. 2015;1(3):95-104. Epub 2015 Oct 23.

12.

Neurogenetics and clinical evidence for the putative activation of the brain reward circuitry by a neuroadaptagen: proposing an addiction candidate gene panel map.

Chen TJ, Blum K, Chen AL, Bowirrat A, Downs WB, Madigan MA, Waite RL, Bailey JA, Kerner M, Yeldandi S, Majmundar N, Giordano J, Morse S, Miller D, Fornari F, Braverman ER.

J Psychoactive Drugs. 2011 Apr-Jun;43(2):108-27.

PMID:
21858957
13.

Dopamine Genetics and Function in Food and Substance Abuse.

Blum K, Oscar-Berman M, Barh D, Giordano J, Gold M.

J Genet Syndr Gene Ther. 2013 Feb 10;4(121). pii: 1000121.

14.

Acute intravenous synaptamine complex variant KB220™ "normalizes" neurological dysregulation in patients during protracted abstinence from alcohol and opiates as observed using quantitative electroencephalographic and genetic analysis for reward polymorphisms: part 1, pilot study with 2 case reports.

Miller DK, Bowirrat A, Manka M, Miller M, Stokes S, Manka D, Allen C, Gant C, Downs BW, Smolen A, Stevens E, Yeldandi S, Blum K.

Postgrad Med. 2010 Nov;122(6):188-213. doi: 10.3810/pgm.2010.11.2236. Review.

PMID:
21084795
15.

Manipulation of catechol-O-methyl-transferase (COMT) activity to influence the attenuation of substance seeking behavior, a subtype of Reward Deficiency Syndrome (RDS), is dependent upon gene polymorphisms: a hypothesis.

Blum K, Chen TJ, Meshkin B, Waite RL, Downs BW, Blum SH, Mengucci JF, Arcuri V, Braverman ER, Palomo T.

Med Hypotheses. 2007;69(5):1054-60. Epub 2007 Apr 30.

PMID:
17467918
16.

Intense, Passionate, Romantic Love: A Natural Addiction? How the Fields That Investigate Romance and Substance Abuse Can Inform Each Other.

Fisher HE, Xu X, Aron A, Brown LL.

Front Psychol. 2016 May 10;7:687. doi: 10.3389/fpsyg.2016.00687. eCollection 2016. Review.

17.

Neuro-Genetics of Reward Deficiency Syndrome (RDS) as the Root Cause of "Addiction Transfer": A New Phenomenon Common after Bariatric Surgery.

Blum K, Bailey J, Gonzalez AM, Oscar-Berman M, Liu Y, Giordano J, Braverman E, Gold M.

J Genet Syndr Gene Ther. 2011 Dec 23;2012(1). pii: S2-001.

18.

Do dopaminergic gene polymorphisms affect mesolimbic reward activation of music listening response? Therapeutic impact on Reward Deficiency Syndrome (RDS).

Blum K, Chen TJ, Chen AL, Madigan M, Downs BW, Waite RL, Braverman ER, Kerner M, Bowirrat A, Giordano J, Henshaw H, Gold MS.

Med Hypotheses. 2010 Mar;74(3):513-20. doi: 10.1016/j.mehy.2009.10.008. Epub 2009 Nov 14.

PMID:
19914781
19.

Overcoming qEEG abnormalities and reward gene deficits during protracted abstinence in male psychostimulant and polydrug abusers utilizing putative dopamine D₂ agonist therapy: part 2.

Blum K, Chen TJ, Morse S, Giordano J, Chen AL, Thompson J, Allen C, Smolen A, Lubar J, Stice E, Downs BW, Waite RL, Madigan MA, Kerner M, Fornari F, Braverman ER.

Postgrad Med. 2010 Nov;122(6):214-26. doi: 10.3810/pgm.2010.11.2237.

PMID:
21084796
20.

Common Neurogenetic Diagnosis and Meso-Limbic Manipulation of Hypodopaminergic Function in Reward Deficiency Syndrome (RDS): Changing the Recovery Landscape.

Blum K, Febo M, Badgaiyan RD, Demetrovics Z, Simpatico T, Fahlke C, M OB, Li M, Dushaj K, Gold MS.

Curr Neuropharmacol. 2017;15(1):184-194. Review.

Supplemental Content

Support Center